Sucampo Pharmaceuticals — Investor Presentation (April 2014)
26 slides from Sucampo Pharmaceuticals's investor presentation, Apr 8, 2014
Slide 1: Corporate Update
© Pharmaceuticals=inc. rate Update Peter Greenleaf Chief Executive Officer Cary Claiborne Chief Financial Officer Silvia Taylor Senior Vice President, Investor Relations and Corporate Communications e 3 SUCAMPO The Science of Innovation
Slide 2: Agenda
Agenda Introductions and Forward-Looking Statements Leadership Update Company Introduction & Value Proposition Commercial Overview Prostone Platform Technology Overview Pipeline and Product Development Guidance Key Upcoming Events Conclusion NO BON ss ‘The Sucampo logo and the tagline. The Science o
Slide 3: Forward-Looking Statements
Looking Statements This presentation contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materiall
Slide 4: Sucampo Leadership Update
Sucampo Leadership Update Peter Greenleaf, CEO + 20 years of biopharmaceutical experience in commercialization, strategic planning & drug development + Former CEO and Director of Histogenics; former President of Medimmune, the worldwide biologics R&D arm of AstraZeneca Daniel Getman, Ph.D., Chairman
Slide 5: Sucampo Value Proposition
Sucampo Value PropositionCommercial=Stage, Global Biopharmaceutical“Gompany + AMITIZA (lubiprostone) in gastroenterology Approved in US chronic idiopathic constipation (CIC), irritable bowel Two Approved syndrome with constipation (IBS-C), and opioid-induced constipation (OIC); UK for CIC; Japan for
Slide 6: AMITIZA U.S.
AMITIZAU.S. Continued AMITIZA YOY Growth mM ° «64: Strongest quarter ever for AMITIZA + Net sales growth of 5% for Q4 + TRx growth of 6% for Q4 * Calendar year high of 1.3M TRx in 2013 AMITIZA * TRx up 5% YoY through December YTD? Market Growth Accelerating * Class up almost 7% for 2H 2013 vs. 1H 20
Slide 7: AMITIZA U.S. (cont.)
} AMITIZA U.S. (cont.) Base Business Remains Strong * Over 8M prescriptions since 20064 + Building on strength in long-term safety + Resonates well with PCPs + Building on strength in managed care access + Preferred managedcare position and significantly lower copay vs. competition + Medicare Part D
Slide 8: Global AMITIZA Approvals and Regulatory Filings
Global AMITIZA Approvals and Regulatory Filings AMITIZA has been used since 2006 with over 8M prescriptions by patients suffering from CIC and IBS-C ia Switzerland CIC (2009) OIC (filed) UK. cic (2012) us. OIC Update coal) CIC (2008) 1BS-C (2008) OIC Approved (April 2013) ¢ 8 $ SUCAMPO The Science o
Slide 9: AMITIZA Global Snapshot
AMITIZA Global Snapshot Japan * Continued success; sales continue to be above our and Abbott's expectations + AMITIZA sales in Japan contributed $16 million to topline in 2013 Europe U.K. * MHRA* did not approve 294 indication in OIC + Evaluating all options for path forward * NICE** endorsement Res
Slide 10: AMITIZA Intellectual Property
AMITIZA Intellectual Property AMITIZA has a robust U.S. patent estate * 13 patents in Orange Book + Latest patents expire in 2027 Paragraph IV certification notice letter to Sucampo received on January 2, 2013 regarding ANDA submitted to FDA by Anchen Pharmaceuticals + Notice letter alleges the 126
Slide 11: RESCULA U.S. Overview
RESCULA U.S. Overview RESCULA Commercial Strategy + Implemented new commercial strategy for RESCULA + Focus on current RESCULA prescribers * Contract sales representatives are spending 20% of time calling on current RESCULA prescribers + Belief in value of continued development of unoprostone isopro
Slide 12: Sucampo's Proprietary Prostone Platform
Sucampo's Proprietary Prostone Platform Technology Sucampo: Only company developing and commercializing prostone compounds globally Prostones: + Functional fatty acids naturally occuring in the human body * lon-channel activators + Physiological mediators of restoration of cellular homeostasis and t
Slide 13: Lubiprostone and Unoprostone Isopropyl Activity
- Unoprostone Lubiprostone isopropyl Fluid Secretion Smooth Muscle Relaxation Barrier Repair and Mucosal Protection yy , Anti-Inflammatory Activity Nerve Stabilization Prevents Neuronal Cell Death e 3 SUCAMPO See Reference 6 The Science of Innovation
Slide 14: Sucampo Prostone Pipeline Key Highlights
Sucampo Prostone Pipeline Key Highlights Lubiprostone Clinical Development & Life Cycle Management Pediatric Functional Constipation + Initiated global P3 clinical program for lubiprostone in children and adolescents aged 6 months to 17 yrs with pediatric functional constipation + Takeda is funding
Slide 15: Sucampo Prostone Pipeline Key Highlights (cont)
Sucampo Prostone Pipeline Key Highlights (cont) lon Channel Activators Cobiprostone for Lumbar Spinal Stenosis for Oral Mucositis Lumbar Spinal Stenosis (LSS) Oral Mucositis + Degenerative change in lumbar spine; unmet medical + P4b study of oral spray formulation of cobiprostone need with limited t
Slide 16: Stage of Clinical Development
CLINICAL FOCUS STAGE OF CLINICAL DEVELOPMENT LEAD COMPOUNDS PRECLINICAL PHASE 1 PHASE 2 PHASE3 SUCCESSFULLY COMPLETED BIPROJECTED START [ONGOING SUCAMPO : *Co-developing with R-Tech Ueno, Ltd. The Science of Innovation rerun Ww
Slide 17: Key Facts: SCMP (NASDAQ)
Trading Symbol SCMP (NASDAQ) Corporate Headquarters Bethesda, MD Stock Price (04-03-14), 52-Week Range $7.11, $11.00 to $5.40 Shares Outstanding (04-03-14) 44.3M (1 class of common stock) Daily Volume (90-day average) 277,557 Market Capitalization (04-03-14) $314.7M Enterprise Value (04-03-14) $271.
Slide 18: Key Upcoming Events
Commercial AMITIZA OIC indication potential approval in Switzerland Clinical End of Pb study in cobiprostone for oral mucositis Start of Phase 1b study for oral ion channel activator in LSS Pediatric lubiprostone safety trial first patient roll over Financial Q1 2014 earnings call Corporate Annual s
Slide 19: Sucampo Value Proposition
Sucampo Value PropositionCommercial=Stage, Global Biopharmaceutical“Gompany + AMITIZA (lubiprostone) in gastroenterology Approved in US chronic idiopathic constipation (CIC), irritable bowel Two FDA-Approved syndrome with constipation (IBS-C), and opioid-induced constipation (OIC); UK for CIC; Japan
Slide 20: ? SUCAMPO
¢ 20 ? SUCAMPO The Science of Innovation
Slide 21: Financial Highlights
ncial Highlights I ‘Key Facts _ BM Financial Hightights for the Full Year of 2013 | Trading Symbol SCMP (NASDAQ) Debt $52.7M Corporate Headquarters Bethesda, MD Cash & Equivalents $95.9M Stock Price (04-03-14), $7.11, $11.00 to Total OperatingExpense | $68.0M 52-Week Range 240 Total Revenue $89.6M S
Slide 22: Terms of Sucampo's AMITIZA Agreements
Terms of Sucampo’s AMITIZA Agreements Takeda Agreement * Takeda shall promote, market, and sell AMITIZA in U.S. and Canada + Sucampo’s tiered royalty rate: 18%-26% of annual net sales + Sucampo earned $20M in upfront and $140M in development milestone payments as of 12/31/13 + Sucampo received $115M
Slide 23: Issued Lubiprostone U.S. Patents
Issued Lubiprostone U:S=PRatents Patent No. Expires Type of Patent 5,284,858" 2014 Composition of matter (drug substance) 6,414,016" 2020 ‘Therapeutic use (treating constipation) 6583,174" 2020 Composition of matter (drug product) 6,982,283" 2022 Therapeutic use (treating OIC) 7084,148° 2022, Therap
Slide 24: Additional Issued Patents
Additional Issued Patents Lubiprostone Ex U.S. Japanese Patent No. Expres Type of Patent 4382,316 2028 Compositionof matter (tug substance anddrugproduct) 4,382,353 2025, Therapeutic use testing 01) 4,684,334 2023 ‘Therapeutic use (treating constipation) 4,785,794 2028 Composition af matter (drug pr
Slide 25: Additional Issued Patents
Additional Issued Patents Unoprostone 5773471 2016 ‘Therapeutic use (treating retintspigmertosa) 6,770,575" 2018 Composttionat matter (drug product) andtherepeuic use (tresting ocular hypertension) 5450836" 2a “Therapeutic use (weating ocular hypertension and glaucoma) 8,609,729 2081 Therapeuticuse
Slide 26: References
References IMS SmartView, NPA Report, client Factored Numbers Camilleri M. Opioid.induced constipation: challenges and therapeutic opportunities. Am J Gastroenterol. 2011 May;106(6):835-42 Clearview Analysis 2008 Internal Research Fingertip Formulary (NOV 2013) Sucampo data on file Radiograph trom B
Sucampo Pharmaceuticals — Investor Presentation (April 2014) on 6ix